Citations (30)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (7)
Yixue Shao & Charles Stoecker. (2020) Cost-effectiveness of pneumococcal vaccines among adults over 50 years old in low- and middle-income countries: a systematic review. Expert Review of Vaccines 19:12, pages 1141-1151.
Read now
Read now
J. P. Sevilla, Andrew Stawasz, Daria Burnes, Anubhav Agarwal, Basak Hacibedel, Kerem Helvacioglu, Reiko Sato & David E. Bloom. (2020) Indirect costs of adult pneumococcal disease and the productivity-based rate of return to the 13-valent pneumococcal conjugate vaccine for adults in Turkey. Human Vaccines & Immunotherapeutics 16:8, pages 1923-1936.
Read now
Read now
Angela R. Wateska, Mary Patricia Nowalk, Chyongchiou J. Lin, Lee H. Harrison, William Schaffner, Richard K. Zimmerman & Kenneth J. Smith. (2019) An intervention to improve pneumococcal vaccination uptake in high risk 50-64 year olds vs. expanded age-based recommendations: an exploratory cost-effectiveness analysis. Human Vaccines & Immunotherapeutics 15:4, pages 863-872.
Read now
Read now
Andrew D. Wiese, Marie R. Griffin & Carlos G. Grijalva. (2019) Impact of pneumococcal conjugate vaccines on hospitalizations for pneumonia in the United States. Expert Review of Vaccines 18:4, pages 327-341.
Read now
Read now
Sara Boccalini, Angela Bechini, Roberto Gasparini, Donatella Panatto, Daniela Amicizia & Paolo Bonanni. (2017) Economic studies applied to vaccines against invasive diseases: An updated budget impact analysis of age-based pneumococcal vaccination strategies in the elderly in Italy. Human Vaccines & Immunotherapeutics 13:2, pages 417-422.
Read now
Read now
Barbara Rita Porchia, Paolo Bonanni, Angela Bechini, Gugliemo Bonaccorsi & Sara Boccalini. (2017) Evaluating the costs and benefits of pneumococcal vaccination in adults. Expert Review of Vaccines 16:2, pages 93-107.
Read now
Read now
A. T. Newall. (2016) What do we know about the cost-effectiveness of pneumococcal conjugate vaccination in older adults?. Human Vaccines & Immunotherapeutics 12:10, pages 2666-2669.
Read now
Read now
Articles from other publishers (23)
Yi-hong Ni, Zhen-hui Xu & Jing Wang. (2023) Understanding vaccine hesitancy with PCV13 in children: Results of a survey in Shanghai, China. PLOS ONE 18:4, pages e0284810.
Crossref
Crossref
Ryan O’Reilly, Sayako Yokoyama, Justin Boyle, Jeffrey C. Kwong, Allison McGeer, Teresa To & Beate Sander. (2021) The impact of acute pneumococcal disease on health state utility values: a systematic review. Quality of Life Research 31:2, pages 375-388.
Crossref
Crossref
Josephine Storch, Carolin Fleischmann-Struzek, Norman Rose, Thomas Lehmann, Anna Mikolajetz, Srikanth Maddela, Mathias W. Pletz, Christina Forstner, Ole Wichmann, Julia Neufeind, Monique Vogel, Konrad Reinhart, Horst Christian Vollmar & Antje Freytag. (2021) The effect of influenza and pneumococcal vaccination in the elderly on health service utilisation and costs: a claims data-based cohort study. The European Journal of Health Economics 23:1, pages 67-80.
Crossref
Crossref
Rajesh Venkitakrishnan, Divya Ramachandran, Jolsana Augustine, Melcy Cleetus, Susan John, Anand Vijay & AparnaSoman Nirmal. (2022) Awareness and attitude about pneumococcal vaccination among nursing staff in a tertiary care institution in Kerala, South India. PULMON 24:3, pages 104.
Crossref
Crossref
Chiara Scelfo, Francesco Menzella, Matteo Fontana, Giulia Ghidoni, Carla Galeone & Nicola Cosimo Facciolongo. (2021) Pneumonia and Invasive Pneumococcal Diseases: The Role of Pneumococcal Conjugate Vaccine in the Era of Multi-Drug Resistance. Vaccines 9:5, pages 420.
Crossref
Crossref
Charles Feldman, Sipho K. Dlamini, Shabir A. Madhi, Susan Meiring, Anne von Gottberg, Janetta C. de Beer, Margreet de Necker & Marthinus P. Stander. (2020) The cost-effectiveness of using pneumococcal conjugate vaccine (PCV13) versus pneumococcal polysaccharide vaccine (PPSV23), in South African adults. PLOS ONE 15:1, pages e0227945.
Crossref
Crossref
Alessandro Sanduzzi, Angelo Canora, Patrizia Belfiore, Marialuisa Bocchino, Renato Liguori & Giorgio Liguori. (2019) Impact of 13Valent Vaccine for Prevention of Pneumococcal Diseases in Children and Adults at Risk: Possible Scenarios in Campania Region. Infectious Disorders - Drug Targets 19:4, pages 403-408.
Crossref
Crossref
Miguel López-Gobernado, Alberto Pérez-Rubio, Eva López-García, Agustín Mayo Iscar, Carlos Cabezas Pascual & Jose María Eiros. (2019) Evaluación económica de la vacunación frente al neumococo en mayores de 65 años de Castilla y León. Revista Española de Geriatría y Gerontología 54:6, pages 309-314.
Crossref
Crossref
Marina Treskova, Stefan M. Scholz & Alexander Kuhlmann. (2019) Cost Effectiveness of Elderly Pneumococcal Vaccination in Presence of Higher-Valent Pneumococcal Conjugate Childhood Vaccination: Systematic Literature Review with Focus on Methods and Assumptions. PharmacoEconomics 37:9, pages 1093-1127.
Crossref
Crossref
Fiona Ecarnot, Stefania Maggi & Jean-Pierre Michel. 2019. Reference Module in Biomedical Sciences. Reference Module in Biomedical Sciences.
Cornelia Betsch, Constanze Rossmann, Mathias W. Pletz, Horst C. Vollmar, Antje Freytag, Ole Wichmann, Regina Hanke, Wolfgang Hanke, Dorothee Heinemeier, Philipp Schmid, Sarah Eitze, Winja Weber, Anne Reinhardt, Nora K. Küpke, Christina Forstner, Carolin Fleischmann-Struzek, Anna Mikolajetz, Josephine Römhild, Julia Neufeind, Thorsten Rieck, Kasia Suchecka & Konrad Reinhart. (2018) Increasing influenza and pneumococcal vaccine uptake in the elderly: study protocol for the multi-methods prospective intervention study Vaccination60+. BMC Public Health 18:1.
Crossref
Crossref
C. Chen, P. Beutels, J. Wood, R. Menzies, C.R. MacIntyre, P. McIntyre & A.T. Newall. (2018) Retrospective cost-effectiveness of the 23-valent pneumococcal polysaccharide vaccination program in Australia. Vaccine 36:42, pages 6307-6313.
Crossref
Crossref
Mélanie Drolet, Élodie Bénard, Mark Jit, Raymond Hutubessy & Marc Brisson. (2018) Model Comparisons of the Effectiveness and Cost-Effectiveness of Vaccination: A Systematic Review of the Literature. Value in Health 21:10, pages 1250-1258.
Crossref
Crossref
Tobias Svensson, Magdalena Kättström, Ylva Hammarlund, Daniel Roth, P.-O. Andersson, Magnus Svensson, Ingmar Nilsson, Lars Rombo, Honar Cherif & Eva Kimby. (2018) Pneumococcal conjugate vaccine triggers a better immune response than pneumococcal polysaccharide vaccine in patients with chronic lymphocytic leukemia A randomized study by the Swedish CLL group. Vaccine 36:25, pages 3701-3707.
Crossref
Crossref
T. Mark Doherty, Mark P. Connolly, Giuseppe Del Giudice, Johan Flamaing, Jorg J. Goronzy, Beatrix Grubeck-Loebenstein, Paul-Henri Lambert, Stefania Maggi, Janet E. McElhaney, Hideaki Nagai, William Schaffner, Ruprecht Schmidt-Ott, Edward Walsh & Alberta Di Pasquale. (2018) Vaccination programs for older adults in an era of demographic change. European Geriatric Medicine 9:3, pages 289-300.
Crossref
Crossref
C. Chen, P. Beutels & A.T. Newall. (2018) Evolution over time in the cost-effectiveness of pneumococcal conjugate vaccine (PCV13) in older Australians due to herd protection from infant vaccination. Vaccine 36:16, pages 2057-2060.
Crossref
Crossref
Jung Yeon Heo, Yu Bin Seo, Won Suk Choi, Jacob Lee, Jin Gu Yoon, Saem Na Lee, Min Joo Choi, Ji Yun Noh, Jin-Young Ahn, Hye Won Jeong, Hee Jin Cheong, Woo Joo Kim, Hee Young Lee & Joon Young Song. (2018) Incidence and case fatality rates of community-acquired pneumonia and pneumococcal diseases among Korean adults: Catchment population-based analysis. PLOS ONE 13:3, pages e0194598.
Crossref
Crossref
S. Dirmesropian, J.G. Wood, C.R. MacIntyre, P. Beutels, P. McIntyre, R. Menzies, J.F. Reyes, C. Chen & A.T. Newall. (2017) Cost-effectiveness of 13-valent pneumococcal conjugate vaccine (PCV13) in older Australians. Vaccine 35:34, pages 4307-4314.
Crossref
Crossref
Charles Stoecker, Lindsay Kim, Ryan Gierke & Tamara Pilishvili. (2016) Incremental Cost-Effectiveness of 13-valent Pneumococcal Conjugate Vaccine for Adults Age 50 Years and Older in the United States. Journal of General Internal Medicine 31:8, pages 901-908.
Crossref
Crossref
Adriaan Blommaert, Joke Bilcke, Lander Willem, Jan Verhaegen, Herman Goossens & Philippe Beutels. (2016) The cost-effectiveness of pneumococcal vaccination in healthy adults over 50: An exploration of influential factors for Belgium. Vaccine 34:18, pages 2106-2112.
Crossref
Crossref
Livio Garattini, Anna Padula & Milene Rangel Da Costa. (2015) Economic Evidence of Pneumococcal Vaccination in Older Adults: Uncertain Modelling or Competitive Tendering?. PharmacoEconomics 34:3, pages 221-224.
Crossref
Crossref
Albert Jan van Hoek & Elizabeth Miller. (2016) Cost-Effectiveness of Vaccinating Immunocompetent ≥65 Year Olds with the 13-Valent Pneumococcal Conjugate Vaccine in England. PLOS ONE 11:2, pages e0149540.
Crossref
Crossref
Renske Eilers, Paul F. M. Krabbe & Hester E. de Melker. (2015) Attitudes of Dutch general practitioners towards vaccinating the elderly: less is more?. BMC Family Practice 16:1.
Crossref
Crossref